passages: 3997
passages: document
passages: Effect of treatment with paromomycin on endotoxemia in patients with alcoholic liver disease -- a double-blind , placebo-controlled trial . The results of experimental and clinical studies support the hypothesis that gut-derived endotoxins might be of relevance for the development and course of alcoholic liver disease . The aim of this study was to test the effect of a nonabsorbable , broad-spectrum antibiotic on endotoxemia in patients with alcoholic liver disease . Fifty patients with alcoholic liver disease ( 27 with cirrhosis , 23 without cirrhosis ) were randomly assigned to receive either paromomycin sulfate ( 3 x 1 g/day ) or placebo in a double-blind fashion for at least 3 weeks , and if possible 4 weeks . Endotoxin concentration , liver function tests , and other laboratory parameters were determined in weekly intervals . Endotoxin concentration was also determined in 15 healthy controls . Groups receiving paromomycin or placebo were similar for clinical and biological items collected initially . Mean initial endotoxin concentrations were significantly elevated in both groups ( mean +/- SEM ; paromomycin , 16.7 +/- 5.3 pg/ml ; placebo , 17.5 +/- 6.9 pg/ml ; healthy controls , 2.3 +/- 0.4 pg/ml ) . Although the mean endotoxin concentration was lower in the verum group after 1 week ( paromomycin , 8.0 +/- 1.9 pg/ml ; placebo , 14.6 +/- 3.5 pg/ml ; p > 0.05 ) , paromomycin treatment had no significant effect on endotoxin concentration or liver function tests during the 4-week period . The beneficial effect of paromomycin treatment on endotoxemia in cirrhotics reported in earlier studies could not be reproduced under the conditions of this trial in patients with alcoholic liver disease .
entities: 3998
entities: Intervention_Pharmacological
entities: paromomycin
entities: 3999
entities: Intervention_Control
entities: placebo-controlled
entities: 4000
entities: Intervention_Pharmacological
entities: paromomycin sulfate
entities: 4001
entities: Intervention_Control
entities: placebo
entities: 4002
entities: Intervention_Pharmacological
entities: paromomycin
entities: 4003
entities: Intervention_Control
entities: placebo
entities: 4004
entities: Intervention_Pharmacological
entities: paromomycin
entities: 4005
entities: Intervention_Control
entities: placebo
entities: 4006
entities: Intervention_Pharmacological
entities: paromomycin
entities: 4007
entities: Intervention_Control
entities: placebo
entities: 4008
entities: Intervention_Pharmacological
entities: paromomycin
entities: 4009
entities: Intervention_Pharmacological
entities: paromomycin
entities: 4010
entities: Outcome_Physical
entities: endotoxemia
entities: 4011
entities: Outcome_Physical
entities: endotoxemia
entities: 4012
entities: Outcome_Physical
entities: Endotoxin concentration
entities: 4013
entities: Outcome_Physical
entities: liver function tests
entities: 4014
entities: Outcome_Physical
entities: Endotoxin concentration
entities: 4015
entities: Outcome_Physical
entities: endotoxin concentrations
entities: 4016
entities: Outcome_Physical
entities: endotoxin concentration
entities: 4017
entities: Outcome_Physical
entities: endotoxin concentration
entities: 4018
entities: Outcome_Physical
entities: liver function tests
entities: 4019
entities: Participant_Condition
entities: patients with alcoholic liver disease
entities: 4020
entities: Participant_Condition
entities: patients with alcoholic liver disease .
entities: 4021
entities: Participant_Sample-size
entities: Fifty
entities: 4022
entities: Participant_Condition
entities: patients with alcoholic liver disease (
entities: 4023
entities: Participant_Sample-size
entities: 27
entities: 4024
entities: Participant_Condition
entities: with cirrhosis ,
entities: 4025
entities: Participant_Sample-size
entities: 23
entities: 4026
entities: Participant_Condition
entities: without cirrhosis )
entities: 4027
entities: Participant_Sample-size
entities: 15
entities: 4028
entities: Participant_Condition
entities: healthy controls
entities: 4029
entities: Participant_Condition
entities: patients with alcoholic liver disease .